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ABSTRACT
Background: 
We wished to determine whether early and late death are associated with different baseline factors 
in intracerebral haemorrhage survivors. 
Methods: 
This is a secondary analysis of the multicentre prospective observational CROMIS-2 ICH study. 
Death was defined as “early” if occurring within 6 months of study entry, and “late” if occurring 
after this time point. 
Results: 
In our cohort (n=1094), there were 306 deaths (per 100 patient-years: absolute event rate 11.7, 
95% CI 10.5 to 13.1); 156 were “early” and 150 “late”. In multivariable analyses, early death was 
independently associated with age (per year increase, HR 1.05, p=0.003), history of hypertension 
(HR 1.89, p=0.038), pre-event mRS (per point increase, HR 1.41, p<0.0001), admission NIHSS 
(per point increase, HR 1.11, p<0.0001), and haemorrhage volume > 60ml (HR 4.08, p<0.0001). 
Late death showed independent associations with age (per year increase, HR 1.04, p=0.003), pre-
event mRS (per point increase, HR 1.42, p=0.001), prior anticoagulant use (HR 2.13, p=0.028) 
and the presence of intraventricular extension (HR 1.73, p=0.033) in multivariable analyses. In 
further analyses where time was treated as continuous (rather than dichotomised), the hazard ratio 
of previous cerebral ischaemic events increased with time, whilst those for GCS, NIHSS and ICH 
volume decreased over time.
Conclusions: 
We provide new evidence that not all baseline factors associated with early mortality after 
intracerebral haemorrhage are associated with mortality after 6 months, and that the effects of 
baseline variables change over time. Our findings could help design better prognostic scores for 
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INTRODUCTION
Most research on outcomes following intracerebral haemorrhage (ICH) has focussed on short term 
mortality (within 6 months), reflecting the high rates of early death associated with this stroke 
subtype(1, 2). Many factors associated with early mortality relate to ICH severity, and this is 
reflected in prognostic scores which aim to predict outcome in the short term(3-11). Policies of 
active acute management including blood pressure lowering, prompt reversal of anticoagulation, 
and neurosurgical referral aim to improve prognosis in patients with ICH(12); an improved 
understanding of the factors that influence “late” death following ICH might identify potentially 
modifiable risk factors that could improve long term outcomes(1).  
Our aim was to evaluate whether early and late death are associated with different baseline factors 
in intracerebral haemorrhage survivors using data from the prospective multicentre CROMIS-2 
ICH study. We hypothesised that factors relating to the severity of the acute ICH would not be 
associated with death at later (beyond 6 months) time points. 
METHODS
Data availability
Analyses for the CROMIS-2 study are ongoing; once all of these analyses are completed, the 
CROMIS-2 Steering Committee will consider applications from other researchers for access to 
anonymised source data.
Participants
We included adults from the CROMIS-2 ICH study (Clinical Relevance of Microbleeds in 
Stroke); full details of the study protocol have been published previously(13). Further details are 
provided in the Supplementary Methods. The study was approved by the National Research Ethics 
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The outcome of interest for this project was time to death. Mortality notifications were received 
from NHS Digital (previously the Health and Social Care Information Centre) as detailed in the 
previously published study protocol(13). NHS Digital is a national centralised body that collects 
data on health and social care in the United Kingdom; mortality data are derived from “hospital 
episode statistics” (records of all NHS patient admissions) and information on registered deaths 
from the Office of National Statistics (death registration is a legal requirement in the United 
Kingdom). 
Patients were censored at either 3 years following the ICH that resulted in study entry, or at last 
available follow-up for vital status (the time of the study’s last notification of deaths from NHS 
Digital: October 31, 2017), depending on which was earlier.
Imaging
Brain CT imaging was acquired acutely at the time of the index event as part of the patient’s 
routine clinical care. Further details are provided in the Supplementary Material. 
Statistics
Statistical analysis was performed using Stata (Version 15.1). We dichotomised time following 
ICH into “early” (before 6 months) and “late” (after 6 months) periods. We used univariable Cox 
regression to calculate hazard ratios (HR) for all baseline variables collected to review for 
associations during these two time periods. Variables where the 95% confidence intervals (CI) did 
not cross 1 were considered as statistically significant. To explore this further, the effect of each 
baseline variable was then allowed to vary linearly with time; further details are provided in the 
Supplementary Material. 
RESULTS
All 1094 patients recruited to CROMIS-2 ICH were included (Table 1). Follow up was for a total 
2613.48 patient-years (median 3.00 years, interquartile range, IQR, 2.31 to 3.00 years).  There 
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patient-years; Figure 1). The median time between the index ICH event and study entry was 4 
days (IQR 2 to 8 days).
Associations of “early” vs “late” death
Of the 306 deaths, 156 occurred within 6 months of the index haemorrhage event (“early”), and 
150 deaths occurred after 6 months and within 3 years of the index ICH (“late”). Baseline 
characteristics for both groups are shown in Table 1. 
Early death (Table 2) was associated with age, hypertension, diabetes mellitus, atrial fibrillation 
(AF), a history of previous cerebral ischaemic events, pre-event modified Rankin scale (mRS), 
anticoagulant use prior to ICH, Glasgow Coma Scale (GCS) and National Institutes of Health 
Stroke Scale (NIHSS) scores at study entry. Imaging features at study entry that were significantly 
associated with early death were Van Swieten score, ICH volume, and the presence of 
intraventricular extension. In a multivariable model including these variables, age at study entry 
(per year increase, HR 1.05, 95% CI 1.02 to 1.08, p=0.003), history of hypertension (HR 1.89, 
95% CI 1.04 to 3.46, p=0.038), pre-event mRS (per point increase, HR 1.41, 95% CI 1.17 to 1.70, 
p<0.0001), admission NIHSS (per point increase, HR 1.11, 95% CI 1.06 to 1.15, p<0.0001), and 
ICH volume > 60ml (HR 4.08, 95% CI 1.85 to 8.96, p<0.0001) remained associated with early 
death.  
When considering death later than 6 months (Table 2), age, AF, smoking, pre-event cognitive 
impairment, previous cerebral ischaemic event, pre-event mRS, anticoagulant use prior to index 
ICH, increasing van Swieten score and the presence of intraventricular extension showed 
significant associations. In a multivariable model including all variables with a significant 
association with late death, only age at study entry (per year increase, HR 1.04, 95% CI 1.02 to 
1.08, p=0.003), pre-event mRS (per point increase, HR 1.42, 95% CI 1.16 to 1.73, p=0.001), 
anticoagulant use prior to ICH (HR 2.13, 95% CI 1.08 to 4.17, p=0.028) and the presence of 
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We then investigated which baseline characteristics showed a significant change in HR between 
the early and the late periods (Table 2). We found that HRs for the presence of APOE ε2, GCS, 
NIHSS, and ICH volume > 60ml showed evidence of significant change between the early and late 
periods (Table 2). 
Further exploratory analysis of time-varying effects
We then performed exploratory analyses where, time was considered as a continuous measure 
(Supplementary Table 1). In these analyses, variables which showed significant time-varying 
effects were history of a previous cerebral ischaemic event (p=0.0214), admission GCS 
(p=0.0108), NIHSS (p<0.00001) and ICH volume (p=0.0439). The hazard ratios of previous 
cerebral ischaemic events increased with time, whilst those for NIHSS and ICH volume decreased 
with time. The protective (negative association) of GCS also decreased with time. 
DISCUSSION
We provide new evidence that not all baseline factors associated with early mortality after 
intracerebral haemorrhage are associated with mortality after 6 months. In analyses where the 
time-varying effect of baseline variables were allowed to vary continuously with time, we found 
that the influence of measures of acute intracerebral haemorrhage severity decreased over time, 
whereas those associated with established cerebrovascular disease (previous cerebral ischaemic 
events) increased over time. These results support the argument that definitions of “early” or 
“late” death are necessarily arbitrary, as the impact of some characteristics present at study entry 
vary continuously with time. 
In our study, the factors that we found were independently associated with early death are in 
keeping with other studies, and reflected in pre-existing prognostic scores which include these and 
other variables(4-11). Differences between our results for associations with late death and those 
previously reported(14, 15) are likely to reflect our method of considering early and late death 
independently; when considering all death events together, we observed similar effects to those 
previously reported. Additionally, we observed that four variables (APOE ε2, GCS, NIHSS and 
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after 6 months (although the hazard ratios for APOE ε2 were not statistically significant in 
themselves). This result confirms that whilst GCS, NIHSS and ICH volume are important 
predictors of early mortality, their effect changes significantly between the early and late periods, 
and thus they are less useful for predicting mortality in the longer-term, as we hypothesised. Our 
analyses of linear time-varying effects on long term mortality following ICH are novel and 
demonstrate the potentially complex interactions that can occur over time. These analyses 
highlight the difficulties in defining what is “early” death, or a “short-term” outcome; further work 
that considers time-varying effects on mortality across longer time scales is needed to guide this. 
Our finding of an association between intraventricular extension with late death seems 
counterintuitive, but illustrates the importance of our work and the complicated manner in which 
baseline variables might interact over time. Given that our cohort included patients with milder 
strokes, we hypothesise that the effect of intraventricular extension on early death was lost in the 
adjusted analyses because of larger magnitude effects associated with other factors associated with 
ICH severity (NIHSS and ICH volume). We speculate when considering late death, the effects of 
acute factors such as NIHSS and ICH volume were of smaller magnitude, and thus the impact of 
intraventricular extension as a measure of stroke severity became more apparent. We did observe, 
in unadjusted analyses, that intraventricular extension was associated with both early and late 
death, but the magnitude of the association was smaller for late death (Table 2).  
Our study has a number of strengths, including the number of patients, its multicentre design 
(which increases generalisability), robust ascertainment of follow up events and the detailed 
clinical and radiological data available for each participant. However, there are  limitations of our 
work. Our cohort is comprised of  survivors with mild strokes, as reflected by the median NIHSS 
and GCS scores, low ICH volumes and low early death rates. This cohort therefore is unlikely to 
be representative of all ICH patients, particularly those with more severe haemorrhages. We were 
unable to adjust for acute complications of ICH, or details relating to immediate care, either active 
or care-limiting (do not resuscitate orders or palliative pathways), all of which would impact 
mortality. Additionally, we were unable to comment on cause of death in our patients. Finally, 
whilst we considered the time-varying effects of variables recorded at study entry, the status of 
these may have changed after this time-point (for example, anti-platelet or anticoagulant use) and 
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We provide new evidence that not all baseline factors associated with early mortality after 
intracerebral haemorrhage are associated with mortality after 6 months.. Our findings could help 
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TABLES
Table 1: Baseline characteristics 







n 1094 788 (72.0) 156 (14.3) 150 (13.7)
Age, years, mean (SD) 73.3 (12.5) 70.3 (12.4) 81.1 (9.4) 80.7 (8.5)
Sex, male, n (%) 628 (57.4) 468 (59.4) 78 (50.0) 82 (54.7)
Hypertension, n (%) 718 (66.7) 505 (65.3) 114 (73.6) 99 (66.9)
Hypercholesterolaemia, n (%) 467 (44.0) 322 (42.0) 71 (47.7) 74 (50.3)
Diabetes mellitus, n (%) 202 (18.6) 132 (16.9) 38 (24.4) 32 (21.6)
AF, n (%) 375 (37.4) 215 (30.1) 81 (56.3) 79 (55.2)
Smoking (at time of ICH), n 
(%)
114 (10.8) 94 (12.4) 12 (8.0) 8 (5.6)
Pre-existing cognitive 
impairment, n (%)
251 (39.8) 150 (34.3) 54 (50.5) 47 (54.7)
Previous cerebral ischaemic 
event, n (%)
241 (22.9) 149 (19.5) 44 (30.1) 48 (33.8)
Previous ICH, n (%) 46 (4.3) 28 (3.6) 10 (6.7) 8 (5.6)
Pre-event mRS, median (IQR) 0 (0 to 1) 0 (0 to 1) 1 (0 to 3) 1 (0 to 2)
APOE ε2, presence, n (%) 189 (20.7) 138 (20.8) 31 (26.5) 20 (15.3)
APOE ε4, presence, n (%) 256 (28.1) 196 (29.5) 24 (20.5) 36 (27.5)
Medications
Anti-platelet use prior to ICH, 
n (%)
267 (24.6) 193 (24.7) 38 (24.5) 36 (24.2)
Anticoagulant use prior to 
ICH, n (%)
436 (40.1) 261 (33.4) 86 (55.5) 89 (59.3)
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(%)
Anticoagulant at discharge, n 
(%)
113 (10.7) 78 (10.2) 14 (9.5) 21 (14.5)
Clinical features at study entry
GCS, median (IQR) 15 (14 to 15) 15 (14 to 15) 14 (11 to 15) 15 (14 to 15)
NIHSS, median (IQR) 7 (3 to 13) 6 (3 to 11) 14 (7 to 19) 6 (3 to 12)
Imaging features at study entry
Lacunes, presence, n (%) 98 (9.0) 69 (8.8) 15 (9.6) 14 (9.3)
Van Swieten Score (WMC), 
median (IQR)
0 (0 to 2) 0 (0 to 2) 1 (0 to 3) 2 (0 to 3)
Infratentorial 99 (9.1) 69 (8.8) 12 (7.7) 18 (12.0)
Deep 546 (50.0) 398 (50.6) 69 (44.2) 79 (52.7)ICH location
Lobar 447 (40.9) 319 (40.6) 75 (48.1) 53 (35.3)
<30ml 886 (85.9) 655 (89.0) 106 (70.7) 125 (85.6)
30 – 60ml 99 (9.6) 60 (8.2) 24 (16.0) 15 (10.3)ICH volume
>60ml 47 (4.6) 21 (2.9) 20 (13.3) 6 (4.1)
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Table 2: Univariable Cox regression analysis for early (before 6 months) and late (after 6 
months) periods following ICH
Univariable hazard ratios for each characteristic obtained by fitting Cox regression models with 
time-varying effects (before/after 6 months). The time-varying coefficient p value compares the 








Age, per year increase 1.08 (1.06 to 1.10) 1.09 (1.07 to 1.11) 0.360
Sex, male 0.73 (0.53 to 1.00) 0.85 (0.62 to 1.18) 0.500
Hypertension 1.43 (1.00 to 2.04) 1.08 (0.77 to 1.52) 0.270
Hypercholesterolaemia 1.18 (0.86 to 1.63) 1.34 (0.97 to 1.85) 0.585
Diabetes mellitus 1.44 (1.00 to 2.07) 1.31 (0.89 to 1.94) 0.729
AF 2.31 (1.66 to 3.21) 2.67 (1.92 to 3.71) 0.548
Smoking, current 0.70 (0.39 to 1.27) 0.45 (0.22 to 0.91) 0.337
Pre-existing cognitive 
impairment
1.32 (0.75 to 2.34) 2.13 (1.39 to 3.25) 0.336
Previous cerebral ischaemic 
event
1.50 (1.05 to 2.13) 1.90 (1.34 to 2.69) 0.345
Previous ICH 1.65 (0.87 to 3.14) 1.49 (0.73 to 3.04) 0.833
Pre-event mRS, per point 
increase
1.56 (1.40 to 1.74) 1.50 (1.33 to 1.69) 0.610
APOE ε2, presence 1.40 (0.93 to 2.11) 0.70 (0.44 to 1.13) 0.032
APOE ε4, presence 0.65 (0.42 to 1.02) 0.90 (0.61 to 1.32) 0.280
Medications
Anti-platelet use prior to 
ICH
0.98 (0.68 to 1.42) 0.96 (0.66 to 1.40) 0.936
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ICH
Anti-platelet at discharge 0.95 (0.46 to 1.93) 1.23 (0.67 to 2.28) 0.582
Anticoagulant at discharge 0.85 (0.49 to 1.48) 1.48 (0.93 to 2.35) 0.134
Clinical features at study entry
GCS, per point increase 0.80 (0.76 to 0.84) 0.93 (0.86 to 1.00) 0.001
NIHSS, per point increase 1.11 (1.08 to 1.14) 1.00 (0.97 to 1.04) <0.0001
Imaging features at study entry
Lacunes, presence 1.05 (0.62 to 1.79) 1.06 (0.61 to 1.84) 0.976
Van Swieten Score (WMC), 
per point increase
1.23 (1.11 to 1.36) 1.37 (1.23 to 1.51) 0.139
Infratentorial Reference group
Deep 1.04 (0.57 to 1.93) 0.79 (0.47 to 1.32) 0.494
ICH 
location
Lobar 1.42 (0.77 to 2.62) 0.67 (0.39 to 1.14) 0.067
<30ml Reference group
30 – 60ml 2.20 (1.41 to 3.42) 1.29 (0.75 to 2.20) 0.131
ICH volume
>60ml 4.85 (3.01 to 7.83)
1.40 (0.62  to 
3.18)
0.010
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